Aug 27, 1976

Treatment of hypertrophic obstructive cardiomyopathy with verapamil, a calcium antagonist (author's transl)

Deutsche medizinische Wochenschrift
M KaltenbachM Keller

Abstract

Cardiac catheterisation with pressure measurements, left-ventricular cine-angiography and selective coronary angiography confirmed the diagnosis of hypertrophic obstructive cardiomyopathy in 20 patients. After a mean observation period of 20 months during which most of them were treated with beta-blockers, verapamil, 480 mg by mouth, was given for an average of 12 months. There was an impressive improvement in symptoms, compared with the state under beta-blocker treatment. There was a significant reduction in the ECG signs of left-ventricular hypertrophy and of the radiologically measured heart volume. Treatment of this condition with verapamil appeared to be superior to that with beta-blockers.

  • References
  • Citations30

References

  • We're still populating references for this paper, please check back later.

Mentioned in this Paper

Calcium
Hypertrophic Cardiomyopathy
Cardiac Catheterization Procedures
Cardiac Volume
Drug Evaluation
Idiopathic Hypertrophic Subaortic Stenosis
Left Ventricular Hypertrophy
Ventricular Hypertrophy
Heart Ventricle
Dexverapamil

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.